ECSP045041A - Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos - Google Patents

Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos

Info

Publication number
ECSP045041A
ECSP045041A EC2004005041A ECSP045041A ECSP045041A EC SP045041 A ECSP045041 A EC SP045041A EC 2004005041 A EC2004005041 A EC 2004005041A EC SP045041 A ECSP045041 A EC SP045041A EC SP045041 A ECSP045041 A EC SP045041A
Authority
EC
Ecuador
Prior art keywords
treatment
acute coronary
coronary syndromes
specific dose
fondaparinux sodium
Prior art date
Application number
EC2004005041A
Other languages
English (en)
Spanish (es)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8181220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of ECSP045041A publication Critical patent/ECSP045041A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024Esters of saccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
EC2004005041A 2001-11-13 2004-03-31 Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos ECSP045041A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01204323 2001-11-13

Publications (1)

Publication Number Publication Date
ECSP045041A true ECSP045041A (es) 2004-04-28

Family

ID=8181220

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005041A ECSP045041A (es) 2001-11-13 2004-03-31 Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos

Country Status (36)

Country Link
US (1) US20040248848A1 (enExample)
EP (1) EP1446131B1 (enExample)
JP (1) JP4523276B2 (enExample)
KR (1) KR20050044318A (enExample)
CN (1) CN1602197A (enExample)
AP (1) AP1820A (enExample)
AR (1) AR037291A1 (enExample)
AT (1) ATE361753T1 (enExample)
AU (1) AU2002351915B2 (enExample)
BR (1) BR0212915A (enExample)
CA (1) CA2465776A1 (enExample)
CO (1) CO5580790A2 (enExample)
CY (1) CY1106765T1 (enExample)
DE (1) DE60220084T2 (enExample)
DK (1) DK1446131T3 (enExample)
EA (1) EA007325B1 (enExample)
EC (1) ECSP045041A (enExample)
ES (1) ES2287343T3 (enExample)
GE (1) GEP20074097B (enExample)
HR (1) HRP20040303B1 (enExample)
HU (1) HU228959B1 (enExample)
IL (2) IL161114A0 (enExample)
IS (1) IS2484B (enExample)
MA (1) MA27071A1 (enExample)
ME (2) ME00229B (enExample)
MX (1) MXPA04003045A (enExample)
NO (1) NO20041320L (enExample)
NZ (1) NZ552129A (enExample)
PE (1) PE20030740A1 (enExample)
PL (1) PL206008B1 (enExample)
PT (1) PT1446131E (enExample)
RS (1) RS50906B (enExample)
SI (1) SI1446131T1 (enExample)
UA (1) UA80399C2 (enExample)
WO (1) WO2003041722A1 (enExample)
ZA (1) ZA200402464B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090075910A1 (en) * 2007-09-13 2009-03-19 Protia, Llc Deuterium-enriched fondaparinux
EP3271405A1 (en) * 2015-03-20 2018-01-24 Aarhus Universitet Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders
US10688249B2 (en) * 2015-06-11 2020-06-23 Virchow Biotech Pvt. Ltd. Multiple dose pharmaceutical compositions containing heparin and/or heparin-like compounds and devices and methods for delivering the same
CN107595769A (zh) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 一种磺达肝癸钠注射液组合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2662442A1 (fr) * 1990-05-23 1991-11-29 Midy Spa Trifluoromethylphenyltetrahydropyridines n-substituees procede pour leur preparation, intermediaires du procede et compositions pharmaceutiques les contenant.
CA2199642C (en) * 1997-03-10 2001-05-08 Roger Cariou Compositions containing an association of aspirin and an anti-xa oligosaccharide and use of an anti-xa oligosaccharide optionally in combination with aspirin
FR2764511B1 (fr) * 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
JP2006501815A (ja) * 2002-04-25 2006-01-19 モメンタ ファーマシューティカルズ インコーポレイテッド 粘膜送達のための方法および製品

Also Published As

Publication number Publication date
US20040248848A1 (en) 2004-12-09
HU228959B1 (en) 2013-07-29
HRP20040303A2 (en) 2004-10-31
RS26704A (sr) 2007-02-05
AP2004003014A0 (en) 2004-06-30
ATE361753T1 (de) 2007-06-15
NO20041320L (no) 2004-06-14
CY1106765T1 (el) 2012-05-23
MA27071A1 (fr) 2004-12-20
KR20050044318A (ko) 2005-05-12
EA007325B1 (ru) 2006-08-25
HRP20040303B1 (hr) 2012-02-29
AP1820A (en) 2008-01-11
MEP1108A (en) 2011-02-10
ME00229B (me) 2011-10-10
MXPA04003045A (es) 2005-06-20
BR0212915A (pt) 2004-10-13
HUP0401462A2 (en) 2006-02-28
JP4523276B2 (ja) 2010-08-11
HK1070561A1 (en) 2005-06-24
CA2465776A1 (en) 2003-05-22
CO5580790A2 (es) 2005-11-30
PL369027A1 (en) 2005-04-18
IL161114A (en) 2010-11-30
ZA200402464B (en) 2005-06-29
EP1446131B1 (en) 2007-05-09
AU2002351915B2 (en) 2007-11-29
RS50906B (sr) 2010-08-31
WO2003041722A1 (en) 2003-05-22
CN1602197A (zh) 2005-03-30
DK1446131T3 (da) 2007-09-10
IL161114A0 (en) 2004-08-31
UA80399C2 (en) 2007-09-25
ES2287343T3 (es) 2007-12-16
HUP0401462A3 (en) 2006-04-28
DE60220084T2 (de) 2008-01-10
SI1446131T1 (sl) 2007-10-31
DE60220084D1 (de) 2007-06-21
IS2484B (is) 2008-12-15
JP2005509007A (ja) 2005-04-07
EA200400382A1 (ru) 2004-10-28
NZ552129A (en) 2008-04-30
PL206008B1 (pl) 2010-06-30
EP1446131A1 (en) 2004-08-18
IS7199A (is) 2004-03-29
PE20030740A1 (es) 2003-08-28
PT1446131E (pt) 2007-08-07
AR037291A1 (es) 2004-11-03
GEP20074097B (en) 2007-05-10

Similar Documents

Publication Publication Date Title
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
ES2076935T3 (es) Compuesto de pirazolopiridina y procedimientos para su preparacion.
CO4940450A1 (es) Formulaciones farmaceuticas que contienen voriconazol
CY1114631T1 (el) Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο
CY1110988T1 (el) Ταχεως αποσαθρουμενο στερεο παρασκευασμα
AR023423A1 (es) Derivados de adamantano, procedimientos para su preparacion, composicion farmaceutica, procedimiento para la preparacion de la composicion farmaceutica, yuso de dichos derivados para la manufactura de medicamentos
AR033859A1 (es) Inhibidores de la metaloproteinasa de la matriz
CY1112274T1 (el) Νεοι ολιγοσακχαριτες, η παρασκευh τους και οι φαρμακευτικες συνθεσεις οι οποιες τους περιεχουν
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
IT1245761B (it) Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
AR037517A1 (es) Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
AR033688A1 (es) Composicion parenteral reconstituible
DE60205870D1 (de) Orale pharmazeutische zusammensetzung aus cefpodoxim-proxetil
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
ECSP024389A (es) Composiciones farmaceuticas solidas de valsartan
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
AR017640A1 (es) Un derivado de carbohidratos, su uso y una composicion farmaceutica que lo comprende
ECSP045041A (es) Uso de una dosis especifica de fondaparinux sodio para el tratamiento de los sindromes coronarios agudos
IT9019793A0 (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
ES2176009T3 (es) Utilizacion de cloruro de sodio para reducir la toxicidad gastrointestinal de los derivados de la competencia.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
UY26530A1 (es) Composición.
DK1411956T3 (da) Anvendelse af oversulfaterede polysaccharider som inhibitorer af HIV
JP2005509007A5 (enExample)